288 related articles for article (PubMed ID: 29253153)
1. Fosfomycin efficacy and emergence of resistance among Enterobacteriaceae in an in vitro dynamic bladder infection model.
Abbott IJ; Meletiadis J; Belghanch I; Wijma RA; Kanioura L; Roberts JA; Peleg AY; Mouton JW
J Antimicrob Chemother; 2018 Mar; 73(3):709-719. PubMed ID: 29253153
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of pooled human urine and synthetic alternatives in a dynamic bladder infection in vitro model simulating oral fosfomycin therapy.
Abbott IJ; van Gorp E; Wijma RA; Meletiadis J; Mouton JW; Peleg AY
J Microbiol Methods; 2020 Apr; 171():105861. PubMed ID: 32035114
[TBL] [Abstract][Full Text] [Related]
3. Impact of bacterial species and baseline resistance on fosfomycin efficacy in urinary tract infections.
Abbott IJ; Dekker J; van Gorp E; Wijma RA; Raaphorst MN; Klaassen CHW; Meletiadis J; Mouton JW; Peleg AY
J Antimicrob Chemother; 2020 Apr; 75(4):988-996. PubMed ID: 31873748
[TBL] [Abstract][Full Text] [Related]
4. Oral Fosfomycin Efficacy with Variable Urinary Exposures following Single and Multiple Doses against
Abbott IJ; van Gorp E; Wijma RA; Meletiadis J; Roberts JA; Mouton JW; Peleg AY
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31907184
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic/pharmacodynamic analysis of oral fosfomycin against Enterobacterales, Pseudomonas aeruginosa and Enterococcus spp. in an in vitro bladder infection model: impact on clinical breakpoints.
Abbott IJ; Mouton JW; Peleg AY; Meletiadis J
J Antimicrob Chemother; 2021 Nov; 76(12):3201-3211. PubMed ID: 34473271
[TBL] [Abstract][Full Text] [Related]
6. Role of inoculum and mutant frequency on fosfomycin MIC discrepancies by agar dilution and broth microdilution methods in Enterobacteriaceae.
Ballestero-Téllez M; Docobo-Pérez F; Rodríguez-Martínez JM; Conejo MC; Ramos-Guelfo MS; Blázquez J; Rodríguez-Baño J; Pascual A
Clin Microbiol Infect; 2017 May; 23(5):325-331. PubMed ID: 28062317
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of single and multiple oral doses of fosfomycin against Pseudomonas aeruginosa urinary tract infections in a dynamic in vitro bladder infection model.
Abbott IJ; van Gorp E; Wijma RA; Dekker J; Croughs PD; Meletiadis J; Mouton JW; Peleg AY
J Antimicrob Chemother; 2020 Jul; 75(7):1879-1888. PubMed ID: 32361749
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic Evaluation of Fosfomycin against Escherichia coli and Klebsiella spp. from Urinary Tract Infections and the Influence of pH on Fosfomycin Activities.
Fedrigo NH; Mazucheli J; Albiero J; Shinohara DR; Lodi FG; Machado ACDS; Sy SKB; Tognim MCB
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607025
[TBL] [Abstract][Full Text] [Related]
9. Oral fosfomycin activity against Klebsiella pneumoniae in a dynamic bladder infection in vitro model.
Abbott IJ; van Gorp E; Wyres KL; Wallis SC; Roberts JA; Meletiadis J; Peleg AY
J Antimicrob Chemother; 2022 Apr; 77(5):1324-1333. PubMed ID: 35211736
[TBL] [Abstract][Full Text] [Related]
10. In Vitro Efficacy of Six Alternative Antibiotics against Multidrug Resistant Escherichia Coli and Klebsiella Pneumoniae from Urinary Tract Infections.
Chen YT; Ahmad Murad K; Ng LS; Seah JT; Park JJ; Tan TY
Ann Acad Med Singap; 2016 Jun; 45(6):245-50. PubMed ID: 27412057
[TBL] [Abstract][Full Text] [Related]
11. The Activity of Fosfomycin Against Extended-Spectrum Beta-Lactamase-Producing Isolates of Enterobacteriaceae Recovered from Urinary Tract Infections: A Single-Center Study Over a Period of 12 Years.
Aris P; Boroumand MA; Rahbar M; Douraghi M
Microb Drug Resist; 2018 Jun; 24(5):607-612. PubMed ID: 29064348
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.
Cho YH; Jung SI; Chung HS; Yu HS; Hwang EC; Kim SO; Kang TW; Kwon DD; Park K
Int Urol Nephrol; 2015 Jul; 47(7):1059-66. PubMed ID: 26026972
[TBL] [Abstract][Full Text] [Related]
13. Oral ciprofloxacin activity against ceftriaxone-resistant Escherichia coli in an in vitro bladder infection model.
Abbott IJ; van Gorp E; Cottingham H; Macesic N; Wallis SC; Roberts JA; Meletiadis J; Peleg AY
J Antimicrob Chemother; 2023 Feb; 78(2):397-410. PubMed ID: 36473954
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic activity of fosfomycin simulating urinary concentrations achieved after a single 3-g oral dose versus Escherichia coli using an in vitro model.
Zhanel GG; Parkinson K; Higgins S; Denisuik A; Adam H; Pitout J; Noreddin A; Karlowsky JA
Diagn Microbiol Infect Dis; 2017 Jul; 88(3):271-275. PubMed ID: 28483306
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan.
Liu HY; Lin HC; Lin YC; Yu SH; Wu WH; Lee YJ
J Microbiol Immunol Infect; 2011 Oct; 44(5):364-8. PubMed ID: 21524974
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics and differential activity of nitrofurantoin against ESBL-positive pathogens involved in urinary tract infections.
Fransen F; Melchers MJ; Meletiadis J; Mouton JW
J Antimicrob Chemother; 2016 Oct; 71(10):2883-9. PubMed ID: 27278898
[TBL] [Abstract][Full Text] [Related]
17. Extended-spectrum β-lactamase-producing Enterobacteriaceae: in vitro susceptibility to fosfomycin, nitrofurantoin and tigecycline.
Al-Zarouni M; Senok A; Al-Zarooni N; Al-Nassay F; Panigrahi D
Med Princ Pract; 2012; 21(6):543-7. PubMed ID: 22722224
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of ceftazidime/avibactam against urinary isolates from patients in a Phase 3 clinical trial programme for the treatment of complicated urinary tract infections.
Stone GG; Bradford PA; Yates K; Newell P
J Antimicrob Chemother; 2017 May; 72(5):1396-1399. PubMed ID: 28088768
[TBL] [Abstract][Full Text] [Related]
19. Progressive increase of resistance in Enterobacteriaceae urinary isolates from kidney transplant recipients over the past decade: narrowing of the therapeutic options.
Origüen J; Fernández-Ruiz M; López-Medrano F; Ruiz-Merlo T; González E; Morales JM; Fiorante S; San-Juan R; Villa J; Orellana MÁ; Andrés A; Aguado JM
Transpl Infect Dis; 2016 Aug; 18(4):575-84. PubMed ID: 27373698
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility to Fosfomycin and Nitrofurantoin of ESBL-Positive
Park KS; Kim DR; Baek JY; Shin A; Kim KR; Park H; Son S; Cho H; Kim YJ
J Korean Med Sci; 2023 Dec; 38(48):e361. PubMed ID: 38084025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
